Which companies are Dezhan Healthcare's closest peers?

The cockpit's peer set: GuangYuYuan Chinese Herbal Medicine (600771.SS), Nxera Pharma (4565.T), Oric Pharmaceuticals (ORIC), Hunan Warrant Pharmaceutical (688799.SS), Bide Pharmatech (688073.SS), City Therapeutics (CTY), Hunan Er-Kang Pharmaceutical (300267.SZ), Wanbangde Pharmaceutical (002082.SZ).

Is Dezhan Healthcare expensive compared with its peers?

On ev / sales it trades at 15.8× against a peer median of 5.1×, 3rd most expensive of 18 in its peer set.

How has Dezhan Healthcare stock performed?

Over six months to 6 Nov 2026 the shares returned -18.1% against -12.8% for the median peer; over one year -29.9%.

← CockpitCompetitor Analysis › 000813.SZ Dezhan Healthcare Co., Ltd. Class AOpen in the cockpit ↗

Dezhan Healthcare Co., Ltd. Class A000813.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum neutral 48

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$928M

US dollars, full cap

Free float

56%

of shares outstanding

$/day

$14.9M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-14.7 pp

WACC 8.0%

Hurdle

n/a

no reverse DCF

Close · CNYCN¥2.98

1D-1.6%

1W+6.0%

1M-6.6%

3M-11.3%

6M-18.1%

YTD-22.4%

1Y-29.9%

ATR %4.0%

52w lowhigh37.0% off high

What Dezhan Healthcare does

Employees: 1,195

Dezhan Healthcare at a glance

Size Dezhan Healthcare (000813.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $928M, the 2449th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥2.98 on 6 Nov 2026.

Performance Over six months the shares fell 18.1%, against -12.8% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.

Growth Revenue fell 10.3% over the last twelve months (peer median +5.5%); the operating margin is -120.8% (peer median 2.6%).

Valuation It trades at 15.8× enterprise value to sales against a peer median of 5.1× (3rd most expensive of 18).

Capital Return on invested capital runs 14.7 points below its cost of capital (8.0% WACC).

Relative performance

Six months, rebased to 100: Dezhan Healthcare against the median of its 20 peers (local-currency closes).

Dezhan Healthcare financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥349M	CN¥393M	CN¥463M	CN¥487M	CN¥561M
Revenue growth	—	-15%	-5%	-13%	—
Gross profit	CN¥215M	CN¥164M	CN¥246M	CN¥235M	CN¥259M
EBITDA	n/a	-CN¥129M	-CN¥510,070	CN¥25.4M	-CN¥60.3M
Net income	-CN¥388M	-CN¥345M	-CN¥20.4M	CN¥83.3M	-CN¥47.0M
Free cash flow	-CN¥270M	-CN¥231M	-CN¥181M	-CN¥31.9M	CN¥127M
Capital expenditure	CN¥222M	CN¥236M	CN¥167M	CN¥160M	CN¥67.6M
Total debt	CN¥129M	CN¥135M	CN¥18.1M	CN¥7.57M	CN¥24.8M

Quarterly statements and history in the cockpit →

Dezhan Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Dezhan Healthcare is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dezhan Healthcare is the large dot.

Dezhan Healthcare competitors and peer comparison

How Dezhan Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dezhan Healthcare against its 20 peers (data as of 6 Nov 2026)
Measure	000813.SZ	Peer median	Rank in peer set
1-month return	-6.6%	-9.1%	8th highest of 20
6-month return	-18.1%	-12.8%	8th lowest of 20
Distance from 52-week high	-37.0%	-31.4%	9th lowest of 21
Revenue growth (TTM)	-10.3%	+5.5%	5th lowest of 19
Operating margin	-120.8%	2.6%	5th lowest of 19
EV / Sales	15.8×	5.1×	3rd most expensive of 18
ROIC minus cost of capital	-14.7 pp	-2.5 pp	3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Dezhan Healthcare 000813.SZ	China	$928M	-18%	-10%	-121%	15.8×	n/a	n/a
GuangYuYuan Chinese Herbal Medicine 600771.SS	China	$930M	-24%	-6%	5%	4.4×	33.2%	+4.2%
Nxera Pharma 4565.T	Japan	$932M	+63%	+24%	14%	5.1×	16.2%	+27.3%
Oric Pharmaceuticals ORIC	United States	$914M	0%	n/a	n/a	n/a	n/a	n/a
Hunan Warrant Pharmaceutical 688799.SS	China	$942M	-20%	+5%	9%	4.7×	n/a	n/a
Bide Pharmatech 688073.SS	China	$912M	+5%	+10%	19%	3.6×	16.7%	+27.7%
City Therapeutics CTY	United States	$944M	n/a	+388%	-442%	n/a	n/a	n/a
Hunan Er-Kang Pharmaceutical 300267.SZ	China	$909M	-33%	-14%	-29%	5.2×	n/a	n/a
Wanbangde Pharmaceutical 002082.SZ	China	$909M	-65%	-11%	-3%	5.9×	-1.2%	-39.5%
Northeast Pharmaceutical 000597.SZ	China	$948M	-10%	-6%	3%	1.0×	-6.8%	-0.7%
Guizhou Bailing Group Pharmaceutical 002424.SZ	China	$907M	-12%	-25%	2%	2.9×	16.2%	-0.2%
Immatics IMTX	United States	$952M	-44%	-65%	-556%	10.7×	n/a	n/a
Beijing Sun-Novo Pharmaceutical Research 688621.SS	China	$894M	-8%	-1%	-2%	6.1×	n/a	n/a
Zhejiang Ausun Pharmaceutical 603229.SS	China	$893M	-27%	+1%	0%	7.1×	n/a	n/a
Aarti Pharmalabs AARTIPHARM.NS	India	$892M	+19%	+13%	18%	4.3×	n/a	n/a
Corvus Pharmaceuticals CRVS	United States	$887M	-32%	n/a	n/a	n/a	n/a	n/a
Procter & Gamble Health PGHL.NS	India	$971M	+4%	+13%	31%	6.3×	5.5%	+9.3%
Kissei Pharmaceutical 4547.T	Japan	$973M	-16%	+6%	6%	1.1×	n/a	n/a
Strides Pharma Science STAR.NS	India	$973M	-13%	+11%	14%	2.1×	18.1%	+7.8%
Jiangsu Yahong Meditech 688176.SS	China	$973M	-12%	+15%	-172%	17.8×	n/a	n/a
Aktis Oncology AKTS	United States	$880M	-15%	+337%	-1,150%	57.5×	n/a	n/a

Questions

Which companies are Dezhan Healthcare's closest peers?: The cockpit's peer set: GuangYuYuan Chinese Herbal Medicine (600771.SS), Nxera Pharma (4565.T), Oric Pharmaceuticals (ORIC), Hunan Warrant Pharmaceutical (688799.SS), Bide Pharmatech (688073.SS), City Therapeutics (CTY), Hunan Er-Kang Pharmaceutical (300267.SZ), Wanbangde Pharmaceutical (002082.SZ).
Is Dezhan Healthcare expensive compared with its peers?: On ev / sales it trades at 15.8× against a peer median of 5.1×, 3rd most expensive of 18 in its peer set.
How has Dezhan Healthcare stock performed?: Over six months to 6 Nov 2026 the shares returned -18.1% against -12.8% for the median peer; over one year -29.9%.